News & Updates

For adults with early type 2 diabetes (T2D) not adequately controlled by diet and exercise alone, treatment with the investigational small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron yields significant reductions in glycated haemoglobin levels, according to data from the phase III ACHIEVE-1 trial.

Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.